Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Oncolytics Biotech Inc. T.ONC

Alternate Symbol(s):  ONCWF | ONCY

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:ONC)

Fundamentals Snapshot (TSX:ONC)

Current News (TSX:ONC)

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

PR Newswire 2 days ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

PR Newswire 13 days ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference

Canada NewsWire May 10, 2022

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

PR Newswire May 5, 2022

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

PR Newswire May 4, 2022

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

PR Newswire May 2, 2022

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire April 28, 2022

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 21, 2022

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine

PR Newswire April 14, 2022

Bullboard Posts (TSX:ONC)

RE:ONCY's OV pelareorep work to neutralize CD47 etc.

Treatment multiple tumors by immune therapy can be achieved by mobilizing both innate and adaptive immunity. The programmed death ligand...
Noteable - 1 day ago

RE:RE:ONCY's GOBLET trial's pancreatic cohort exceeds expectations

Below is further background in a 2020 paper of CD47's fibrotic reaction in sclerodoma for example: "Scleroderma is a...
Noteable - 2 days ago

ONCY's OV pelareorep work to neutralize CD47 etc.

As recently posted, the relationship between the CD47 "don't eat me" signal / CD47 antibodies / and the oncolytic virus...
Noteable - 2 days ago

RE:ONCY's GOBLET trial's pancreatic cohort exceeds expectations

As background - Pandy et al (2019) found that high CEACAM6 expression is associated with low cytolytic T-cell activity in both basal and...
Noteable - 2 days ago

Why is the stock price going down?

Any thoughts as to why the SP is going down after this very promising & encouraging news?
Snowdrift - 2 days ago

ONCY's GOBLET trial's pancreatic cohort exceeds expectations

June 28, 202 - "With Stage 1's pre-specified efficacy threshold met after just the first three patients, the GOBLET trial&...
Noteable - 2 days ago